TY - JOUR
KW - buprenorphine– naloxone
KW - COVID-19
KW - Telemedicine
KW - Retention
KW - opioid use disorder
KW - Empirical Study
KW - Longitudinal Study
KW - Retrospective Study
KW - Quantitative Study
KW - Human
KW - naloxone
KW - Pandemics
KW - buprenorphine
KW - Drug Therapy
KW - Substance use treatment
KW - article
KW - US
KW - 3383:Drug & Alcohol Rehabilitation
AU - Jagdeep Kaur
AU - Irakli Mania
AU - Raghavendra Tirupathi
AU - Lakshmi Polavarapu
A1 - 
AD - Department of Psychiatry and Behavioral Sciences, University of California Davis, Sacramento, CA, US jagkaur@ucdavis.edu; Keystone Behavioral Health, Chambersburg, PA, US ; Keystone Infectious Disease, Chambersburg, PA, US ; Sadler Health Center, Carlisle, PA, US ; Kaur, Jagdeep,2230 Stockton Boulevard,Sacramento,US,95817,Department of Psychiatry and Behavioral Sciences, University of California Davis,jagkaur@ucdavis.edu
BT - Journal of Rural Mental Health
C5 - Education & Workforce; HIT & Telehealth; Opioids & Substance Use
CP - 2
DO - 10.1037/rmh0000206
IS - 2
JF - Journal of Rural Mental Health
LA - English
M1 - Journal Article
PY - 2022
SN - 1935-942X, 1935-942X
SP - 75
EP - 81
EP - 
T1 - Impact of telemedicine on retention in Medications for Opioid Use Disorder (MOUD) treatment with buprenorphine in the times of COVID-19 pandemic: A retrospective chart review
T2 - Journal of Rural Mental Health
TI - Impact of telemedicine on retention in Medications for Opioid Use Disorder (MOUD) treatment with buprenorphine in the times of COVID-19 pandemic: A retrospective chart review
U1 - Education & Workforce; HIT & Telehealth; Opioids & Substance Use
U3 - 10.1037/rmh0000206
UR - https://www.proquest.com/scholarly-journals/impact-telemedicine-on-retention-medications/docview/2635261675/se-2?accountid=28100
VL - 46
VO - 1935-942X, 1935-942X
Y1 - 2022
Y2 - 04
ER -